Overview
SRRK market data
Price History
SRRK price chart · 1M
- O
- 59.30
- H
- 59.69
- L
- 58.94
- C
- 59.30
- Vol
- 28,911.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $59.30
- Previous Close
- $60.09
- Day High
- $59.69
- Day Low
- $58.94
- 52 Week High
- $61.75
- 52 Week Low
- $43.32
- 7 Day Return
- +7.35%
- 30 Day Return
- +20.21%
- 90 Day Return
- +20.27%
- 1 Year Return
- +28.15%
- Daily Notional Volume
- $1.7M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.47 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -237.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $27.07 – $61.76 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.7B · P/B 18.30 · P/S 140.89.
Company News
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026Benzinga · Aug 21, 2026, 1:11 PM
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63Benzinga · Aug 13, 2026, 3:09 PM
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on ScheduleBenzinga · Aug 10, 2026, 4:03 PM
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price TargetBenzinga · Aug 10, 2026, 2:22 PM
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price TargetBenzinga · Aug 10, 2026, 10:07 AM
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60Benzinga · Aug 7, 2026, 8:35 PM
Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Using Second Fill-Finish SiteBenzinga · Aug 7, 2026, 8:22 PM
8-K filing — Scholar Rock Holding Corp (SRRK)SEC EDGAR · Aug 6, 2026, 12:49 PM
Scholar Rock Holding shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 6, 2026, 12:25 PM
Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492MBenzinga · Aug 6, 2026, 11:04 AM